Volume 94 Issue 42 | p. 15 | Concentrates
Issue Date: October 24, 2016

Merck ups Spanish drug capacity 50%

Department: Business
Keywords: pharmaceuticals, expansion, Spain, medicine

Merck KGaA has increased its biotech drug production capacity in Spain by 50% by expanding its facility in Tres Cantos, near Madrid, at a cost of $16 million. As part of the project, the German firm has increased staffing at the site by 20% to 170. Tres Cantos is Merck’s primary location for producing the active substances for the fertility treatment Gonal-f and growth hormone disorder treatment Saizen. Merck says it has invested about $275 million in health care manufacturing during 2016.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment